Contrasting Straumann (SAUHF) and Biolase (BIOL)

Straumann (OTCMKTS: SAUHF) and Biolase (NASDAQ:BIOL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Volatility & Risk

How to Become a New Pot Stock Millionaire

Straumann has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Biolase has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500.

Valuation and Earnings

This table compares Straumann and Biolase’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Straumann $931.55 million 11.08 $233.11 million $12.04 53.99
Biolase $46.93 million 0.71 -$16.85 million N/A N/A

Straumann has higher revenue and earnings than Biolase.

Analyst Recommendations

This is a breakdown of recent recommendations for Straumann and Biolase, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Straumann 0 0 0 0 N/A
Biolase 0 0 1 0 3.00

Biolase has a consensus target price of $2.50, suggesting a potential upside of 669.23%. Given Biolase’s higher possible upside, analysts clearly believe Biolase is more favorable than Straumann.

Profitability

This table compares Straumann and Biolase’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Straumann N/A N/A N/A
Biolase -35.91% -67.04% -39.50%

Insider and Institutional Ownership

36.2% of Biolase shares are held by institutional investors. 3.2% of Biolase shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Straumann beats Biolase on 6 of the 11 factors compared between the two stocks.

Straumann Company Profile

Straumann Holding AG provides tooth replacement solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, biomaterials, and digital solutions for use in tooth replacement and restoration or to prevent tooth loss. The company offers replacement solutions, including soft tissue level and bone level implants; SLActive surface for bone formation; Roxolid for use in dental implantology; and ceramic implants. It also provides prosthetic components and tools, as well as precision instruments, guided surgery tools, and handling components. In addition, the company offers digital solutions, including guided surgery, intra-oral scanning, and CADCAM; and oral tissue regeneration solutions comprising Emdogain, bone substitutes, membranes, soft tissue grafts, and fleeces. Further, it provides training and education services to its customers. The company offers its products to general dentists, specialists, and dental technicians/laboratories in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

Biolase Company Profile

BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine in the United States and internationally. The company offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. Its dental imaging products comprise 3Shape Trios intraoral scanner and digital impression systems for high-speed digital 3-D picture taking; Galaxy BioMill CAD/CAM system that enables dental practitioners to design, scan, mill, and finish crowns, inlays, and veneers inside the dental office; and CEFLA NewTom VGi and VG3 3-D cone beam computed tomography devices. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply